Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial …Sacramento BeePhase III study of ibrutinib in combination with bendamustine and rituximab in patients with relapsed/refractory CLL/SLL: A randomized, multi-center Phase III, do…
TG Therapeutics, Inc. Initiates a Phase I/II Clinical Trial of Its Novel Third …NASDAQ… the company's novel third-generation anti-CD20 monoclonal antibody, for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) who wer…
Pharmacyclics Reports Fourth Quarter And Full Year Fiscal 2012 Financial …Daily MarketsPhase III study of ibrutinib in combination with bendamustine and rituximab in patients with relapsed/refractory CLL/SLL: A randomized, multi-center Phase III, dou…
Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial …The Herald | HeraldOnline.comPhase III study of ibrutinib in combination with bendamustine and rituximab in patients with relapsed/refractory CLL/SLL: A randomized, multi-cente…
BiolineRX licenses Clal Biotech unit leukemia drugGlobesPre-clinical studies show that BL-8040 is efficient, both alone and in combination with the anti-cancer drug Rituximab, in reducing bone marrow metastasis of lymphoma cells and stimulating lymphom…
Dr Reddy's plans EU launch for biosimilar cancer treatmentZenopaDr Reddy's Laboratories is planning to launch a biosimilar version of Roche's non-Hodgkin's lymphoma treatment rituximab in Europe. The company is in talks with European re…
Pharmaceutical sector roundup: UR AssociatesMoneycontrol.comThe original form of the drug is called Rituximab, and is sold by its innovator Roche AG. Reddy's effort to launch the world's first MAb “biosimilar” is expected to happen jointly …
Spectrum Pharmaceuticals: Raj Sets The Record Straight And Quiets The …Seeking AlphaHe acknowledged that logistical issues and certain requirements for physicians have limited the sales of Zevalin. He compared the drug with the blockbuster lymphoma d…
Emcure to make, market Roche productsHindu Business LineThe second is Rituximab, sold as Mabthera, a drug for non-Hodgkin's lymphoma and rheumatoid arthritis. Similarly, this partnership will be extended to Roche's patented products in India cu…
Clinical Oncology NewsAssistant Director Hematology & Stem Cell Transplantation ProgramClinical Oncology NewsThe Study Group Indolent Lymphomas (StiL) NHL1 trial demonstrated a progression-free survival (PFS) benefit and improved tolerability with …